We are almost there: in 2019, the 2011/62/EU directive containing measures to increase safety in the supply chain of medicinal products will become mandatory in almost all European countries.
Usually these are referred to as serialisation requirements. There is nothing new in absolute terms because, with only a few exceptions, these same rules exist in the United States, Turkey, China, Brazil etc.
The drug industry is in turmoil, also due to the high cost of converting packaging lines.
Not Falorni however, who has also been strengthened by its experience with international markets, has developed a partnership with Antares Vision (a global leader in the provision of integrated serialisation systems), and is therefore already able to offer services in line with the new FMD anti-counterfeiting legislation.
But that is not enough: Falorni is already investing in increasing the number of lines for serialised packaging, so that none of its clients (present or future) will be left behind.
In line with Falorni’s ability to anticipate ever-evolving pharmaceutical market demands, all serialisation lines are and will be equipped with aggregation systems for pallet management.